Corcept Therapeutics Incorporated — Form 8-K Summary
Business context and reporting period
Corcept Therapeutics filed a Form 8-K dated September 22, 2026, with the report signed on September 23, 2026. The filing reports a senior executive transition and related consulting arrangement; it does not provide periodic financial results. The company’s common stock trades on Nasdaq under the symbol CORT.
Financial metrics and liquidity
- The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.
- No financial statements or financial guidance are included.
Material changes
- Sean Maduck, President of Corcept Endocrinology, notified the board of his resignation effective October 1, 2026.
- The filing states that Mr. Maduck’s resignation was not due to any disagreement concerning the company’s operations, financial statements, policies, or practices.
- Justin Gunn will succeed Mr. Maduck, according to the September 23, 2026 press release furnished as Exhibit 99.1. The filing text does not provide further details regarding Mr. Gunn’s background or terms.
Compensation, outlook, risks, and unusual items
- Under a consulting agreement effective October 1, 2026, Mr. Maduck will advise the chief executive officer and executive management team.
- The initial consulting term ends September 30, 2027, unless terminated earlier. Either party may terminate upon 30 days’ prior written notice.
- Mr. Maduck will receive a cash fee of $57,000 per month, implying $684,000 over a full 12-month term before any early termination, subject to the agreement’s terms.
- His previously awarded and outstanding stock options will continue to vest according to their original schedules during the consulting term.
- The complete consulting agreement will be filed as an exhibit to the company’s Form 10-Q for the quarter ending September 30, 2026, or by amendment to this Form 8-K.
- No updated business outlook, specific risks, contingencies, or operational impact from the transition is disclosed.
Investor verification items
- Verify the full consulting agreement, including termination provisions, total potential compensation, and the value and vesting status of outstanding options.
- Review the September 23, 2026 press release for additional details about Justin Gunn’s appointment and the transition.
- Assess the transition’s potential effect on Corcept Endocrinology and executive oversight in subsequent filings.
- Confirm any financial or operating updates in the company’s next quarterly filing, as this Form 8-K contains no financial performance data.